OWC Pharmaceutical Research Corp Successfully Tests Unique, Innovative Delivery Formulation Aimed at Multiple Myeloma Therapy.

Our newly developed, highly concentrated formulation, OWC-1808, was administered in vivo for the first time and was found to be safe and tolerable. This formulation will allow the delivery of very high doses of CBD and THC with exceptional bioavailability, and will be directed initially at our ongoing program for treating Multiple Myeloma.

Continue Reading
Close Menu